Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 1,629 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: In The Mix Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Addressing Microaggressions in Racially Charged Patient-provider Interactions: A Pilot Randomized Trial

NCT04180956
View directory record Official record
Conditions
Racism
Interventions
Bias-reduction Intervention
Other
Lead sponsor
University of Washington
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production

NCT03063645
View directory record Official record
Conditions
Healthy
Interventions
AC-1202, AC-SD-01 (50 g), AC-SD-01 (75 g)
Drug
Lead sponsor
Cerecin
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 30, 2026, 6:14 PM EDT
Enrolling by invitation Phase 1 Interventional

Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

NCT05376553
View directory record Official record
Conditions
Locally Advanced Head and Neck Squamous Cell Carcinoma
Interventions
Cemiplimab, Cisplatin, Docetaxel
Drug
Lead sponsor
Krzysztof Misiukiewicz
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 30, 2026, 6:14 PM EDT
Withdrawn Phase 1 Interventional

Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants

NCT00002956
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Athlete Whey Protein Sensitivity: Prevalence and Performance

NCT05482997
View directory record Official record
Conditions
Food Intolerance
Interventions
Whey Protein Concentrate, Pea Protein Isolate, Rice Protein Concentrate, Hemp Protein
Dietary Supplement
Lead sponsor
University of the Incarnate Word
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Not applicable Interventional Results available

Health Literacy Intervention for Informed Consent of Cancer Patients Considering Clinical Trial Participation

NCT01964222
View directory record Official record
Conditions
Cancer
Interventions
Decision Aid (DA)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 3 Interventional

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation

NCT00014391
View directory record Official record
Conditions
Cancer
Interventions
palivizumab, ribavirin
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 30, 2026, 6:14 PM EDT
Recruiting Phase 2 Interventional

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

NCT07605416
View directory record Official record
Conditions
Plasma Cell Leukemia
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Fludeoxyglucose F-18, Lenalidomide, Magnetic Resonance Imaging, Melphalan, Plerixafor, Positron Emission Tomography, Recombinant Granulocyte Colony-Stimulating Factor, Stem Cell Isolation, Teclistamab, Transthoracic Echocardiography Test
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
11
States / cities
La Jolla, California • New Haven, Connecticut • North Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 1 Interventional

Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis

NCT00003368
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
45
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia

NCT02458287
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Bococizumab 150mg, Bococizumab 75mg, Bococizumab 150mg placebo, Bococizumab 75mg placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
30
States / cities
Chandler, Arizona • Lincoln, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Not applicable Interventional Results available

Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome

NCT01113385
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Steroid Resistant Nephrotic Syndrome
Interventions
D-Galactose
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
2 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Oct 30, 2026, 6:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

An Open-Label, Two-Arm Pilot Study of the Tolerability, Consumer Acceptability, and Exploratory Well-Being Outcomes of a Multi-Ingredient Protein Formula in Two Flavors in Healthy Adults

NCT07827014
View directory record Official record
Conditions
Healthy
Interventions
Vanilla Protein Formula, Chocolate Protein Formula
Dietary Supplement
Lead sponsor
Qualia Life Sciences
Industry
Eligibility
21 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cannabidiol Effects on Blood Alcohol Level and Intoxication

NCT06105138
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
200mg Cannabidiol oral solution, 30mg Cannabidiol oral solution, Placebo
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
21 Years to 60 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 30, 2026, 6:14 PM EDT
Recruiting No phase listed Observational

Lung Function Monitoring During Hypoxemia Episodes

NCT06535074
View directory record Official record
Conditions
Hypoxemia of Newborn
Interventions
Detecting changes in lung volume with hypoxemia episodes
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 4 Interventional Results available

LIBERATE - LIposomal Bupivacaine vERsus Adjuncts in Total shouldErs

NCT03887650
View directory record Official record
Conditions
Post-operative Pain, Total Shoulder Arthroplasty, Osteoarthritis of the Shoulder, Pain Management
Interventions
Liposomal Bupivicaine 1.3%, Bupivacaine 0.5%
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 1 Interventional

A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving

NCT01684150
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders
Interventions
EPZ-5676
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Scottsdale, Arizona • Chicago, Illinois • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 30, 2026, 6:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identification of β Cell Dysfunction in Relatives of Individuals With Type 1 Diabetes Mellitus

NCT04362917
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
There is no intervention
Other
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation

NCT02458235
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions
azacitidine, donor lymphocyte infusion
Drug · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 29 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing

NCT05857930
View directory record Official record
Conditions
Recurrent Wheezing, Wheezing Lower Respiratory Illness
Interventions
OM-85, Placebo
Drug
Lead sponsor
OM Pharma SA
Industry
Eligibility
6 Months to 72 Months
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of a Nutritional Supplement on Skin Health in Generally Healthy Adults

NCT03771807
View directory record Official record
Conditions
Skin Health
Interventions
Beauty From Within, Placebo, Facial cleansing
Dietary Supplement · Other
Lead sponsor
Pharmanex
Industry
Eligibility
40 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 3 Interventional Results available

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

NCT01968967
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Bococizumab (PF-04950615; RN316), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
155
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 115 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 30, 2026, 6:14 PM EDT
Not listed Early Phase 1 Interventional

Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation

NCT03292445
View directory record Official record
Conditions
Immune Tolerance
Interventions
Immune tolerance after kidney transplant, Donor blood stem cells and T cells
Procedure · Drug
Lead sponsor
Samuel Strober
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Palo Alto, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 30, 2026, 6:14 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Practice-Based Intervention To Improve Care for a Diverse Population Of Women With Urinary Incontinence

NCT05534412
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Academic Detailing, Electronic Clinical Decision Support, APP Co-management, Electronic Referral
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
4
States / cities
La Jolla, California • Los Angeles, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 30, 2026, 6:14 PM EDT
Recruiting Phase 2 Interventional

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

NCT05096481
View directory record Official record
Conditions
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
Interventions
PEP-CMV, Temozolomide, Tetanus Diphtheria Vaccine
Biological · Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
3 Years to 39 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
13
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 30, 2026, 6:14 PM EDT